Lymphoma (includes NHL, HL, CNS Lymphoma)

Serum Marker IDs Likely Responders to CAR-T Therapy in Lymphoma

(MedPage Today) Apr 19, 2017 - Patients achieving complete, durable remissions in relapsed/refractory non-Hodgkin lymphoma following low-dose conditioning chemotherapy and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tended to be those with high serum levels of interleukin-15 (IL-15), researchers said.

read article (free registration required)

Novartis CAR-T Cell Therapy CTL019 Receives FDA Breakthrough Therapy Designation For Treatment Of Adult Patients With R/R DLBCL

(Yahoo! Finance) Apr 18, 2017 - Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL); r/r DLBCL, an aggressive cancer with limited options, is the second indication for CTL019 to receive Breakthrough Therapy designation; advances in CTL019 result from collaboration with the University of Pennsylvania; regulatory submissions for r/r DLBCL are expected to be filed by the end of the year.

read article

Novartis Snags Coveted FDA 'Breakthrough' Label for CAR-T, Trial Results Still Under Wraps

(TheStreet) Apr 18, 2017 - Results from the Novartis cell therapy cancer clinical trial known as JULIET remain out of sight to investors -- and its close competitor Kite Pharma -- but the Swiss pharma giant did snag a Breakthrough Therapy Designation from the FDA after sharing the trial data with regulators.

read article

Scientists Work To Strengthen The Synergy Of Chemotherapy And Immunotherapy Against Cancer

(MCG at Augusta/Jagwire News) Apr 17, 2017 - In the war on cancer, powerful chemotherapy agents are increasingly packaged with immunotherapy that primes a patient’s immune system to better battle the disease.

read press release

The Endangered ‘Good Doctor’

(Wall Street Journal) Apr 17, 2017 - The late Burton Lee, a renowned oncologist and physician to President George H.W. Bush, is remembered as both a life saver and a tragic figure by one of his patients.

read article (paid subscription required)

Medivir Announces Positive Data From the Phase II Study Of Remetinostat In Patients With Early-Stage Cutaneous T-Cell Lymphoma

(Medivir AB) Apr 7, 2017 - Medivir AB today announces the completion of the phase II clinical study of the topical, skin-directed histone deacetylase (HDAC) inhibitor, remetinostat, in patients with early stage CTCL.

read corporate press release

Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma

(Yahoo! Finance) Apr 10, 2017 - Alexo Therapeutics, a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint exploited by cancer cells to evade the immune system, today announced that it has initiated dosing in its Phase 1 clinical program evaluating the safety of ALX148 in patients with advanced solid tumors and lymphoma.

read article

Collaboration Helps Make Clinical Trials Possible

(UW Health) Apr 5, 2017 - While the UW Carbone Cancer Center is housed in Madison, it brings world-class cancer care to nearly every corner of the state through the Wisconsin Oncology Network (WON), a collaboration of 19 member clinics across the state and region.

read press release

Novartis Keeps 'JULIET' Study Results Close as Investors and Rival Kite Pharma Wait

(TheStreet) Apr 5, 2017 - Juliet, where art thou? I'm referring to the Novartis clinical trial known as JULIET, investigating the use of the company's genetically altered cell therapy CTL019 in patients with diffuse large B-cell lymphoma (DLBCL) whose disease has returned or is unresponsive to prior treatments.

read article

Kite Wins ‘Clinical Trial Result of the Year' For Its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients With Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards

(Kite Pharma) Apr 6, 2017 - Kite Pharma, Inc., today announced that it won the Clinical Trial Result of the Year award for ZUMA-1, its pivotal CAR-T trial of axicabtagene ciloleucel, in patients with refractory aggressive B-cell non-Hodgkin lymphoma (NHL) at the Clinical and Research Excellence (CARE) Awards.

read corporate press release

The Leukemia and Lymphoma Society Expands its Innovative Therapy Acceleration Program® (TAP) with a Novel Immunotherapy for Lymphoma Patients

(The Business Journal) Apr 5, 2017 - The Leukemia & Lymphoma Society (LLS) continues to advance the promising field of immunotherapy research, harnessing the body’s own immune system to fight cancer, with a $4 million funding commitment in an investigational therapy being developed by Forty Seven Inc. for lymphoma patients.

read article

CAR-T Race Heats Up As Kite, Novartis Complete Filings to FDA

(BioPharma Dive) Apr 2, 2017 - Dive Brief: CAR-T therapy took another step to becoming a commercial reality over the past week as both Kite Pharma and Novartis completed filings to the Food and Drug Administration for their respective treatments, setting the stage for potential approvals to come later this year.

read article

Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Cancer Research Annual Meeting

(Kite) Apr 2, 2017 - Kite Pharma, Inc., today announced two plenary presentations of positive data from the primary analysis of ZUMA-1 for its lead CAR-T candidate, axicabtagene ciloleucel, in patients with refractory aggressive B-cell non-Hodgkin lymphoma (NHL) at the 2017 American Association of Cancer Research Annual Meeting in Washington, D.C.

read corporate press release

New Gene Therapy for Cancer Offers Hope to Those With No Options Left

(NBCNews.com) Mar 31, 2017 - Dimas Padilla thought he was dying for sure. He'd been through the wringer with a type of blood cancer called non-Hodgkin's lymphoma. First, he tried chemotherapy, and then, when the cancer came back a year and a half later, he underwent a bone marrow transplant.

read article

Seattle Genetics Presents Data Advancing Antibody-Drug Conjugate and Novel Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting

(Seattle Genetics) Apr 3, 2017 - Seattle Genetics, Inc., a global biotechnology company, today highlighted multiple data presentations that support the company’s advancing antibody-drug conjugate (ADC) and immuno-oncology programs at the upcoming 108th Annual Meeting of the American Association for Cancer Research (AACR) being held April 1-5, 2017, in Washington, D.C.

read corporate press release

Karyopharm Shakes Off Clinical Hold For Lead Cancer Med

(BioPharma Dive) Mar 30, 2017 - Karyopharm got the go-ahead on Thursday to continue several studies of its lead candidate less than a few weeks after regulators placed them on partial clinical hold — an update that indicated problems with the trials were administrative in nature.

read article

Novartis Makes Plans For Its Cancer-Killing T Cells

(Forbes) Mar 29, 2017 - There's a race on to be the first company to launch what's a CAR-T -- a technology that genetically alters cancer patients' white blood cells to kill tumor cells.

read article

Phase II Study of Daratumumab in Non-Hodgkin's Lymphoma Will Not Proceed to Stage 2 of Trial

(Genmab) Mar 30, 2017 - Genmab A/S announced today that its collaboration partner for daratumumab, Janssen Biotech, Inc., has decided not to initiate stage 2 of the Phase II study (CARINA, LYM2001) of daratumumab in three types of relapsed or refractory non-Hodgkin's lymphoma (NHL).

read corporate press release

FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers

(Genentech) Mar 29, 2017 - The FDA has set an action date of June 26 to make a final decision on approval.

read corporate press release

Dinutuximab for Neuroblastoma and Other EU Decisions

(Medscape Medical News) Mar 24, 2017 - The European authorities have recommended approval of several products used in cancer treatment at their latest meeting, including a new drug for neuroblastoma.

read article (free registration required)
Next Page